These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 30426764)
1. Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease. Casella JF; Adams RJ; Brambilla DJ; Strouse JJ; Maier P; Dlugash R; Avadhani R; Vermillion K; Tonascia J; Voeks JH; Hanley DF; Thompson RE; Lehmann HP Clin Trials; 2019 Feb; 16(1):20-31. PubMed ID: 30426764 [TBL] [Abstract][Full Text] [Related]
2. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Ware RE; Schultz WH; Yovetich N; Mortier NA; Alvarez O; Hilliard L; Iyer RV; Miller ST; Rogers ZR; Scott JP; Waclawiw M; Helms RW Pediatr Blood Cancer; 2011 Dec; 57(6):1011-7. PubMed ID: 21826782 [TBL] [Abstract][Full Text] [Related]
3. Hydroxyurea lowers transcranial Doppler flow velocities in children with sickle cell anaemia in a Nigerian cohort. Lagunju I; Brown BJ; Sodeinde O Pediatr Blood Cancer; 2015 Sep; 62(9):1587-91. PubMed ID: 25847050 [TBL] [Abstract][Full Text] [Related]
4. The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis. Hasson C; Veling L; Rico J; Mhaskar R Medicine (Baltimore); 2019 Dec; 98(51):e18225. PubMed ID: 31860969 [TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea can be used in children with sickle cell disease and cerebral vasculopathy for the prevention of chronic complications? A meta-analysis. Núñez RM; Figueroa CAP; García-Perdomo HA J Child Health Care; 2020 Mar; 24(1):64-77. PubMed ID: 30606035 [TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea use in prevention of stroke recurrence in children with sickle cell disease in a developing country: A cost effectiveness analysis. Cunningham-Myrie C; Abdulkadri A; Waugh A; Bortolusso Ali S; King LG; Knight-Madden J; Reid M Pediatr Blood Cancer; 2015 Oct; 62(10):1862-4. PubMed ID: 25929458 [TBL] [Abstract][Full Text] [Related]
8. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131 [TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study. Casella JF; Furstenau DK; Adams RJ; Brambilla DJ; Lebensburger JD; Fehr JJ; Jordan LC; King AA; Ichord RN; McKinstry RC; Kraut MA; Shaw DW; White DA; Whyte-Stewart DA; Avadhani R; Barron-Casella EA; Cannon AD; Eaton CK; Riekert KA; Shay JE; Smith-Seidel CA; Weiss DC; Ostapkovich ND; Vermillion K; Treine KE; Kingsbury CE; Strouse JJ; Thompson RE; Hanley DF Am J Hematol; 2024 Jul; ():. PubMed ID: 38953438 [TBL] [Abstract][Full Text] [Related]
10. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Greenway A; Ware RE; Thornburg CD Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640 [TBL] [Abstract][Full Text] [Related]
11. Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. Debaun MR; Field JJ Hematology Am Soc Hematol Educ Program; 2007; ():482-8. PubMed ID: 18024668 [TBL] [Abstract][Full Text] [Related]
12. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Wang WC Curr Opin Hematol; 2007 May; 14(3):191-7. PubMed ID: 17414206 [TBL] [Abstract][Full Text] [Related]
13. Primary prevention of stroke in children with sickle cell anemia in sub-Saharan Africa: rationale and design of phase III randomized clinical trial. Abdullahi SU; Wudil BJ; Bello-Manga H; Musa AB; Gambo S; Galadanci NA; Aminu H; Tijjani Gaya A; Sanusi S; Tabari MA; Galadanci A; Borodo A; Abba MS; Dambatta AH; Haliru L; Gambo A; Cassell H; Rodeghier M; Ghafuri DL; Covert Greene BV; Neville K; Kassim AA; Kirkham F; Trevathan E; Jordan LC; Aliyu MH; DeBaun MR Pediatr Hematol Oncol; 2021 Feb; 38(1):49-64. PubMed ID: 33236662 [TBL] [Abstract][Full Text] [Related]
14. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Galadanci NA; Umar Abdullahi S; Vance LD; Musa Tabari A; Ali S; Belonwu R; Salihu A; Amal Galadanci A; Wudil Jibir B; Bello-Manga H; Neville K; Kirkham FJ; Shyr Y; Phillips S; Covert BV; Kassim AA; Jordan LC; Aliyu MH; DeBaun MR Am J Hematol; 2017 Aug; 92(8):780-788. PubMed ID: 28439953 [TBL] [Abstract][Full Text] [Related]
15. Neurologic and Cognitive Outcomes in Sickle Cell Disease from Infancy through Adolescence. Mayer SL; Fields ME; Hulbert ML Neoreviews; 2021 Aug; 22(8):e531-e539. PubMed ID: 34341160 [TBL] [Abstract][Full Text] [Related]
16. Stroke recurrence in Nigerian children with sickle cell disease treated with hydroxyurea. Lagunju IA; Brown BJ; Sodeinde OO Niger Postgrad Med J; 2013 Sep; 20(3):181-7. PubMed ID: 24287747 [TBL] [Abstract][Full Text] [Related]
17. Stroke recurrence in children with sickle cell disease treated with hydroxyurea following first clinical stroke. Ali SB; Moosang M; King L; Knight-Madden J; Reid M Am J Hematol; 2011 Oct; 86(10):846-50. PubMed ID: 21898530 [TBL] [Abstract][Full Text] [Related]
18. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Sumoza A; de Bisotti R; Sumoza D; Fairbanks V Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569 [TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes? Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936 [TBL] [Abstract][Full Text] [Related]